董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William Waddill | 男 | Lead Independent Director | 68 | 43.82万美元 | 6.12 | 2026-03-19 |
| Hongbo Lu | 女 | Independent Director | 55 | 42.07万美元 | 6.30 | 2026-03-19 |
| Adeoye Olukotun | 男 | Independent Director | 81 | 42.07万美元 | 3.82 | 2026-03-19 |
| Victoria Vakiener | 女 | Independent Director | 62 | 42.44万美元 | 4.03 | 2026-03-19 |
| Christopher Anzalone | 男 | Chairman and Chief Executive Officer and Director and President | 56 | 902.99万美元 | 379.27 | 2026-03-19 |
| Mauro Ferrari | 男 | Independent Director | 66 | 42.07万美元 | 7.36 | 2026-03-19 |
| Michael S. Perry | 男 | Independent Director | 66 | 42.82万美元 | 12.77 | 2026-03-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Patrick O Brien | 男 | Chief Operating Officer | 62 | 303.02万美元 | 54.74 | 2026-03-19 |
| James Hamilton | 男 | Chief Medical Officer | 48 | 296.62万美元 | 24.70 | 2026-03-19 |
| Daniel Apel | 男 | Chief Financial Officer | 60 | 195.49万美元 | 17.62 | 2026-03-19 |
| Christopher Anzalone | 男 | Chairman and Chief Executive Officer and Director and President | 56 | 902.99万美元 | 379.27 | 2026-03-19 |
董事简历
中英对照 | 中文 | 英文- William Waddill
-
William Waddill的职业生涯始于30年前的商业银行和公共会计，并已在生物技术行业超过25年。自2016年以来，他一直担任Protagonist Therapeutics（位于加利福尼亚州纽瓦克的临床阶段生物制药公司）的董事会成员，最近于2014年至2016年担任临床阶段制药公司Calithera Bioscience的高级副总裁兼首席财务官。加入Calithera之前，Waddill从2007年到2014年担任Oncomed Pharmaceuticals高级副总裁和首席财务官。Waddill先生曾担任生物技术公司Ilypsa，Inc.的高级副总裁兼首席财务官，该公司于2007年被Amgen，Inc.收购。在加入ILYPSA之前，他曾担任Square One Finance（一家金融咨询公司）的创始人和负责人，Waddill先生曾担任Exelixis，Inc.（一家生物技术公司）的财务和行政高级总监。Waddill先生在芝加哥伊利诺伊大学（University of Illinois，Chicago）获得会计学学士学位，并在波士顿普华永道会计师事务所（PricewaterhouseCoopers）和德勤会计师事务所（Deloitte）工作后获得不活跃会计师认证。
William Waddill began his career over 35 years ago in commercial banking and public accounting and has been in the biotechnology indtry for over 30 years. He currently serves on the boards of Protagonist Therapeutics (Nasdaq: PTGX), and Annexon, Inc. (Nasdaq: ANNX), both clinical stage biopharmaceutical companies, and he previoly served on the board of Turnstone Biologics. Mr. Waddill was Senior Vice President and CFO of Calithera Biosciences, from 2014 to 2016 and Senior Vice President and CFO at OncoMed Pharmaceuticals from 2007 to 2014, both of which re then public biopharmaceutical companies. Prior to that, he served as the Senior Vice President and CFO of llypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. Before joining llypsa, he served as the founder and principal at Square One Finance, a financial consulting biness. Mr. Waddill received a B.S. in accounting from the University of Illinois, Chicago, and certification as a public accountant (inactive) after working at PriceWaterhoeCoopers and Deloitte in Boston. - William Waddill的职业生涯始于30年前的商业银行和公共会计，并已在生物技术行业超过25年。自2016年以来，他一直担任Protagonist Therapeutics（位于加利福尼亚州纽瓦克的临床阶段生物制药公司）的董事会成员，最近于2014年至2016年担任临床阶段制药公司Calithera Bioscience的高级副总裁兼首席财务官。加入Calithera之前，Waddill从2007年到2014年担任Oncomed Pharmaceuticals高级副总裁和首席财务官。Waddill先生曾担任生物技术公司Ilypsa，Inc.的高级副总裁兼首席财务官，该公司于2007年被Amgen，Inc.收购。在加入ILYPSA之前，他曾担任Square One Finance（一家金融咨询公司）的创始人和负责人，Waddill先生曾担任Exelixis，Inc.（一家生物技术公司）的财务和行政高级总监。Waddill先生在芝加哥伊利诺伊大学（University of Illinois，Chicago）获得会计学学士学位，并在波士顿普华永道会计师事务所（PricewaterhouseCoopers）和德勤会计师事务所（Deloitte）工作后获得不活跃会计师认证。
- William Waddill began his career over 35 years ago in commercial banking and public accounting and has been in the biotechnology indtry for over 30 years. He currently serves on the boards of Protagonist Therapeutics (Nasdaq: PTGX), and Annexon, Inc. (Nasdaq: ANNX), both clinical stage biopharmaceutical companies, and he previoly served on the board of Turnstone Biologics. Mr. Waddill was Senior Vice President and CFO of Calithera Biosciences, from 2014 to 2016 and Senior Vice President and CFO at OncoMed Pharmaceuticals from 2007 to 2014, both of which re then public biopharmaceutical companies. Prior to that, he served as the Senior Vice President and CFO of llypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. Before joining llypsa, he served as the founder and principal at Square One Finance, a financial consulting biness. Mr. Waddill received a B.S. in accounting from the University of Illinois, Chicago, and certification as a public accountant (inactive) after working at PriceWaterhoeCoopers and Deloitte in Boston.
- Hongbo Lu
-
Hongbo Lu自2020年4月以来一直担任我们的董事会成员。她自2021年1月起担任风险投资公司Vivo Capital的管理合伙人。她此前曾于2017年1月至2020年12月担任风险投资公司Lilly Asia Ventures的管理合伙人。2011年6月至2016年10月，她曾担任OrbiMed Advisors LLC的董事总经理。陆博士目前担任几家私人生物技术公司的董事会成员，例如PINS Medical，Inc.，Elpiscience和Geneception。她曾于2017年5月至2019年5月担任上市公司董事会成员，包括上市生物技术公司Turning PointTherapeutics，Inc.，并于2018年5月至2019年2月担任上市生物技术公司Avedro，Inc.的董事会成员。陆博士在中国清华大学获得材料科学与工程本科学位，在华盛顿大学获得生物工程博士学位，在加州大学伯克利分校获得工商管理硕士学位。
Hongbo Lu has served as a founding member of NEXTBio Capital, a biotech investment firm, since 2024. Dr. Lu has over 20 years of healthcare investment experience in both public securities and private companies, including her tenure as a Managing Partner of Vivo Capital, LLC, an investment firm, from 2020 to 2024, as a Managing Partner at Lilly Asia Ventures (LAV), a venture capital firm, from 2017 to 2020, and as a Managing Director at OrbiMed Advisors, an investment firm, from 2011 to 2016. Over her investment career, Dr. Lu served on the boards of over 20 healthcare companies, including Turning Point Therapeutics, Crown Biosciences, Avedro, BlossomHill, Createrna, Avistone, Echosens, and was extensively involved in the company formations of ADARx, Ribox, Visirna, Ablaze, Elpiscience, and Ronovo. She currently serves on the boards of Terns Pharmaceuticals (Nasdaq: TERN) and Zenas (Nasdaq: ZBIO). Dr. Lu started her Wall Street career as a biotechnology analyst at Piper Jaffray & Co. and prior to that, her scientific career in biotechnology startups in the Bay Area. - Hongbo Lu自2020年4月以来一直担任我们的董事会成员。她自2021年1月起担任风险投资公司Vivo Capital的管理合伙人。她此前曾于2017年1月至2020年12月担任风险投资公司Lilly Asia Ventures的管理合伙人。2011年6月至2016年10月，她曾担任OrbiMed Advisors LLC的董事总经理。陆博士目前担任几家私人生物技术公司的董事会成员，例如PINS Medical，Inc.，Elpiscience和Geneception。她曾于2017年5月至2019年5月担任上市公司董事会成员，包括上市生物技术公司Turning PointTherapeutics，Inc.，并于2018年5月至2019年2月担任上市生物技术公司Avedro，Inc.的董事会成员。陆博士在中国清华大学获得材料科学与工程本科学位，在华盛顿大学获得生物工程博士学位，在加州大学伯克利分校获得工商管理硕士学位。
- Hongbo Lu has served as a founding member of NEXTBio Capital, a biotech investment firm, since 2024. Dr. Lu has over 20 years of healthcare investment experience in both public securities and private companies, including her tenure as a Managing Partner of Vivo Capital, LLC, an investment firm, from 2020 to 2024, as a Managing Partner at Lilly Asia Ventures (LAV), a venture capital firm, from 2017 to 2020, and as a Managing Director at OrbiMed Advisors, an investment firm, from 2011 to 2016. Over her investment career, Dr. Lu served on the boards of over 20 healthcare companies, including Turning Point Therapeutics, Crown Biosciences, Avedro, BlossomHill, Createrna, Avistone, Echosens, and was extensively involved in the company formations of ADARx, Ribox, Visirna, Ablaze, Elpiscience, and Ronovo. She currently serves on the boards of Terns Pharmaceuticals (Nasdaq: TERN) and Zenas (Nasdaq: ZBIO). Dr. Lu started her Wall Street career as a biotechnology analyst at Piper Jaffray & Co. and prior to that, her scientific career in biotechnology startups in the Bay Area.
- Adeoye Olukotun
-
Adeoye Olukotun于2018年9月成为董事。Olukotun博士自2000年以来一直担任医疗产品咨询公司CR Strategies，LLC的首席执行官，并于2014年至2018年1月担任制药公司Epigen Pharmaceuticals，Inc.的首席执行官。Olukotun博士于2012年至2016年担任制药公司Cardovax，Inc.的副董事长，并于2006年至2012年担任其首席执行官。他还是制药公司Via Pharmaceuticals，Inc.的联合创始人，从2004年到2008年担任该公司的首席医疗官。
Adeoye Olukotun is a Mayo Clinic trained cardiologist who has served as Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial design and FDA strategy for pharmaceutical development, since 2001. Dr. Olukotun currently serves on the board of directors of Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a commercial stage biopharmaceuticals company. He served as CEO of Epigen Pharmaceuticals, Inc., a discovery phase biotechnology company, from 2014 to 2017, and as Vice Board Chair of CardioVax, Inc., a clinical stage biopharmaceutical company, from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol Myers Squibb, and Mallinckrodt. - Adeoye Olukotun于2018年9月成为董事。Olukotun博士自2000年以来一直担任医疗产品咨询公司CR Strategies，LLC的首席执行官，并于2014年至2018年1月担任制药公司Epigen Pharmaceuticals，Inc.的首席执行官。Olukotun博士于2012年至2016年担任制药公司Cardovax，Inc.的副董事长，并于2006年至2012年担任其首席执行官。他还是制药公司Via Pharmaceuticals，Inc.的联合创始人，从2004年到2008年担任该公司的首席医疗官。
- Adeoye Olukotun is a Mayo Clinic trained cardiologist who has served as Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial design and FDA strategy for pharmaceutical development, since 2001. Dr. Olukotun currently serves on the board of directors of Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a commercial stage biopharmaceuticals company. He served as CEO of Epigen Pharmaceuticals, Inc., a discovery phase biotechnology company, from 2014 to 2017, and as Vice Board Chair of CardioVax, Inc., a clinical stage biopharmaceutical company, from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol Myers Squibb, and Mallinckrodt.
- Victoria Vakiener
-
Victoria Vakiener目前在Chimerix（纳斯达克股票代码：CMRX）的董事会任职，该公司是一家临床阶段的生物制药公司。从2018年11月到2021年9月，她在Epizyme, Inc.担任首席商务官，该公司是一家生物制药公司，于2022年被收购，她在那里建立了商业机构，并在六个月内推出了TAZVERIK用于两个适应症。在加入Epizyme之前，Vakiener女士在强生公司（纽约证券交易所代码：JNJ）担任了20多年的高管，在该公司担任领导职务，在公司的制药和诊断业务中承担着越来越大的责任。Vakiener女士的制药生涯始于Schering-Plough，在那里她从事了九年的科学和商业工作。Vakiener女士在奥尔布赖特学院获得生物化学学士学位。
Victoria Vakiener served on the board of directors and chaired the nominating committee at Chimerix, Inc., a clinical stage biopharmaceutical company, until its acquisition by Jazz Pharmaceuticals in April 2025. From November 2018 through September 2021, she served as Chief Commercial Officer of Epizyme, Inc., a commercial stage biopharmaceutical company, where she built the commercial organization and launched TAZVERIK for two indications within six months. Prior to joining Epizyme, Ms. Vakiener was an executive at Johnson & Johnson, a pharmaceutical company, for more than 20 years where she held positions of leadership with increasing responsibility across the company's pharmaceutical and diagnostics binesses. Ms. Vakiener began her pharmaceutical career at Schering Plough, where she spent nine years in both scientific and commercial roles. Ms. Vakiener received a B.S. in Biochemistry from Albright College. - Victoria Vakiener目前在Chimerix（纳斯达克股票代码：CMRX）的董事会任职，该公司是一家临床阶段的生物制药公司。从2018年11月到2021年9月，她在Epizyme, Inc.担任首席商务官，该公司是一家生物制药公司，于2022年被收购，她在那里建立了商业机构，并在六个月内推出了TAZVERIK用于两个适应症。在加入Epizyme之前，Vakiener女士在强生公司（纽约证券交易所代码：JNJ）担任了20多年的高管，在该公司担任领导职务，在公司的制药和诊断业务中承担着越来越大的责任。Vakiener女士的制药生涯始于Schering-Plough，在那里她从事了九年的科学和商业工作。Vakiener女士在奥尔布赖特学院获得生物化学学士学位。
- Victoria Vakiener served on the board of directors and chaired the nominating committee at Chimerix, Inc., a clinical stage biopharmaceutical company, until its acquisition by Jazz Pharmaceuticals in April 2025. From November 2018 through September 2021, she served as Chief Commercial Officer of Epizyme, Inc., a commercial stage biopharmaceutical company, where she built the commercial organization and launched TAZVERIK for two indications within six months. Prior to joining Epizyme, Ms. Vakiener was an executive at Johnson & Johnson, a pharmaceutical company, for more than 20 years where she held positions of leadership with increasing responsibility across the company's pharmaceutical and diagnostics binesses. Ms. Vakiener began her pharmaceutical career at Schering Plough, where she spent nine years in both scientific and commercial roles. Ms. Vakiener received a B.S. in Biochemistry from Albright College.
- Christopher Anzalone
-
Christopher Anzalone， 2007年12月1日，他成为公司的总裁、首席执行官及董事。2005年，Anzalone博士在Benet Group LLC公司担任首席执行官。Benet Group LLC是一家创建纳米生物科技公司的私募股权公司。在Benet集团工作期间，他是两家投资组合公司Nanotope公司（一家研究组织再生的公司）和Leonardo Biosystems公司（一家癌症药物递送公司）的创业总裁。他是Arrowhead公司全资控股子公司Arrowhead Madison 公司和多数控股子公司Calando 制药、Ablaris Therapeutics公司、Tego Biosciences公司，以及少数投资公司Leonardo Biosystems的董事。1999年至2003年，他是华盛顿特区私人股本公司Galway Partners, LLC的合伙人。他在该公司负责采购、组织和建立新企业。他是NanoInk公司（一家领先的纳米公司）的创业总裁。他在加州大学洛杉矶分校获得生物学博士学位；在劳伦斯大学获得管理学学士学位。
Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007 and has led the Company's biness and technical development since then. Prior to joining Arrowhead, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm foced on creating and building new nano biotechnology companies from university generated science. Before his tenure at the Benet Group, from 1999 to 2003, he was a partner at the Washington, DC based private equity firm Galway Partners, LLC, where he was responsible for scing, structuring and building new biness ventures. Dr. Anzalone holds a Ph.D in Biology from UCLA and a B.A. in Government from Lawrence University. - Christopher Anzalone， 2007年12月1日，他成为公司的总裁、首席执行官及董事。2005年，Anzalone博士在Benet Group LLC公司担任首席执行官。Benet Group LLC是一家创建纳米生物科技公司的私募股权公司。在Benet集团工作期间，他是两家投资组合公司Nanotope公司（一家研究组织再生的公司）和Leonardo Biosystems公司（一家癌症药物递送公司）的创业总裁。他是Arrowhead公司全资控股子公司Arrowhead Madison 公司和多数控股子公司Calando 制药、Ablaris Therapeutics公司、Tego Biosciences公司，以及少数投资公司Leonardo Biosystems的董事。1999年至2003年，他是华盛顿特区私人股本公司Galway Partners, LLC的合伙人。他在该公司负责采购、组织和建立新企业。他是NanoInk公司（一家领先的纳米公司）的创业总裁。他在加州大学洛杉矶分校获得生物学博士学位；在劳伦斯大学获得管理学学士学位。
- Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007 and has led the Company's biness and technical development since then. Prior to joining Arrowhead, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm foced on creating and building new nano biotechnology companies from university generated science. Before his tenure at the Benet Group, from 1999 to 2003, he was a partner at the Washington, DC based private equity firm Galway Partners, LLC, where he was responsible for scing, structuring and building new biness ventures. Dr. Anzalone holds a Ph.D in Biology from UCLA and a B.A. in Government from Lawrence University.
- Mauro Ferrari
-
Mauro Ferrari目前担任Washington州西雅图的华盛顿大学药剂学副教授以及德克萨斯州休斯顿的BrYet Pharmaceutics的首席执行官。从2010年到2019年，Ferrari博士曾在Houston Methodist医院担任多个不同职务，包括Houston Methodist医院研究所（TMHRI）总裁兼首席执行官、Houston Methodist医院执行副总裁以及该医院学术附属机构纽约威尔康奈尔医学院的高级副院长。Ferrari博士是国际公认的癌症治疗、纳米医学和生物医学纳米技术专家。他之前的学术任命包括在他毕业的母校加州大学伯克利分校、俄亥俄州立大学担任终身教授，在德克萨斯大学健康科学中心担任纳米医学和生物医学工程系教授和系主任，在MD安德森癌症中心担任实验治疗教授，并在莱斯大学担任生物工程兼职教授。2003年至2005年，Ferrari博士在国家癌症研究所担任纳米技术特别专家和著名学者。他获得了许多国家和国际奖项和表彰。
Mauro Ferrari has served as Affiliate Professor of Pharmaceutics at the University of Washington in Seattle, WA since 2019. He has also served as CEO and Chairman of the Board of BrYet , Inc., a biotech company, since 2019. From 2010 to 2019, Dr. Ferrari served at the Hoton Methodist Hospital in multiple roles, including: President and CEO of The Hoton Methodist Hospital Research Institute (TMHRI), Executive Vice President of Hoton Methodist Hospital, and Senior Associate Dean of ill Cornell Medical College in New York. He also previoly served as President of the European Research Council. Dr. Ferrari was formerly a Professor and chair of the Department of NanoMedicine and Biomedical Engineering at the University of Texas Health Science Center at Hoton, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University, and Adjunct Professor of Biomedical Engineering at the University of Texas in Atin. His previo academic appointments include tenured professorships at his graduate Alma Mater U.C. Berkeley and The Ohio State University. From 2003 to 2005, Dr. Ferrari served as Special Expert on Nanotechnology and Eminent Scholar at The National Cancer Institute. He previoly served on the board of the University of St. Thomas in Hoton. He has also served as CEO of DXT Therapeutics. - Mauro Ferrari目前担任Washington州西雅图的华盛顿大学药剂学副教授以及德克萨斯州休斯顿的BrYet Pharmaceutics的首席执行官。从2010年到2019年，Ferrari博士曾在Houston Methodist医院担任多个不同职务，包括Houston Methodist医院研究所（TMHRI）总裁兼首席执行官、Houston Methodist医院执行副总裁以及该医院学术附属机构纽约威尔康奈尔医学院的高级副院长。Ferrari博士是国际公认的癌症治疗、纳米医学和生物医学纳米技术专家。他之前的学术任命包括在他毕业的母校加州大学伯克利分校、俄亥俄州立大学担任终身教授，在德克萨斯大学健康科学中心担任纳米医学和生物医学工程系教授和系主任，在MD安德森癌症中心担任实验治疗教授，并在莱斯大学担任生物工程兼职教授。2003年至2005年，Ferrari博士在国家癌症研究所担任纳米技术特别专家和著名学者。他获得了许多国家和国际奖项和表彰。
- Mauro Ferrari has served as Affiliate Professor of Pharmaceutics at the University of Washington in Seattle, WA since 2019. He has also served as CEO and Chairman of the Board of BrYet , Inc., a biotech company, since 2019. From 2010 to 2019, Dr. Ferrari served at the Hoton Methodist Hospital in multiple roles, including: President and CEO of The Hoton Methodist Hospital Research Institute (TMHRI), Executive Vice President of Hoton Methodist Hospital, and Senior Associate Dean of ill Cornell Medical College in New York. He also previoly served as President of the European Research Council. Dr. Ferrari was formerly a Professor and chair of the Department of NanoMedicine and Biomedical Engineering at the University of Texas Health Science Center at Hoton, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University, and Adjunct Professor of Biomedical Engineering at the University of Texas in Atin. His previo academic appointments include tenured professorships at his graduate Alma Mater U.C. Berkeley and The Ohio State University. From 2003 to 2005, Dr. Ferrari served as Special Expert on Nanotechnology and Eminent Scholar at The National Cancer Institute. He previoly served on the board of the University of St. Thomas in Hoton. He has also served as CEO of DXT Therapeutics.
- Michael S. Perry
-
Michael S. Perry， 2011年12月，加入Arrowhead公司董事会。他在诺华制药公司的干细胞疗法研究的全球总监。2005年至2012年11月，在诺华制药任职之前，他是Bay City Capital LLP公司的投资合伙人。2010年至2012年11月， 他是Poniard制药公司的首席医学官。他现任AmpliPhi Biosciences Corporation APHB.PK 公司和Avita Medical （ASX：AVH and OTCQX：AVMXY）公司的董事。2005年4月至2009年5月，他是VIA制药公司的首席开发官。该公司一家药品研发的上市公司。在那之前，2003年6月至2005年4月，他是 Extropy制药公司的主席兼首席执行官。该公司是一家私营儿科专业制药公司。2002年至2003年，Perry博士担任Baxter 生物科学公司研发部门的全球总监。1997年至2000年，他是SyStemix Inc. 公司和 Genetic Therapy Inc.公司的总裁兼首席执行官。两家公司都是诺华集团的全资子公司。1994年至1997年，他是诺华制药（前身是Sandoz 制药）的法规事务的副总裁。1994年之前，他在辛泰克公司 （Syntex Corporation）、先灵葆雅公司（Schering-Plough Corporation）和BioResearch Laboratories, Inc公司担任过多个管理职务。Perry博士在加拿大安大略省圭而夫大学获得了动物医学博士学位、生物医药理学博士学位、物理学学士学位。他毕业于哈佛商学院国际管理项目系。
Michael S. Perry is currently a Venture Partner with Bioscience Managers, a global venture capital firm. Dr. Perry was Chief Executive Officer of Avita Medical, Inc., a regenerative medicine company based in Valencia, CA (Nasdaq: RCEL) from 2017 to 2022. From 2014 to 2017, he served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp., the affiliate of Switzerland based Novartis AG, a global pharmaceutical company. Dr. Perry has also served as SVP and Global Head of R&D at Baxter Healthcare, and as President and as CEO of Cell & Gene Therapy at Novartis AG. Earlier in his career he served as VP Regulatory Affairs at Novartis Pharmaceuticals, Sandoz Pharmaceuticals, and Syntex Corporation. He also served as Director of Regulatory Affairs at Schering Plough Corporation. Dr. Perry also served as a Venture Partner with Bay City Capital, LLC for eight years. Dr. Perry has previoly served as a board member for the following companies: Ampliphi Bioscience Corp., Gamida Cell Ltd., Targeted Genetics, Inc., American Xeno, Inc., 7 Hills Pharma, BioTransplant, Inc., ltamar Biomedical Ltd., Systemix, Inc., Genetic Therapy, Inc., Extropy Pharmaceuticals, Inc., and Pharsight Corp. Dr. Perry served as Chair of the Compensation Committee at Ampliphi Bioscience Corp., Genetic Therapy Inc., and at Gamida Cell Ltd. He has also served as a member of the Audit Committee at several biotech companies and as Chairman or member of the Nomination Committee. Dr. Perry additionally served as board Chairman at American Xeno Inc., Extropy Pharmaceuticals Inc., and at 7 Hills Pharma, Inc. Dr. Perry holds an Honors Bachelor of Science in Physics and Engineering and a Ph.D. in Biomedical Pharmacology from the University of Guelph. He also holds a Doctor of Veterinary Medicine & Surgery from the Ontario Veterinary College and is a graduate of the International Advanced Management Program at Harvard Biness School. Dr. Perry currently serves as Adjunct Professor at the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Camp and as Faculty at Hoton Methodist and Chair of the Translational Medicine Advisory Board of the Hoton Methodist Research Institute. - Michael S. Perry， 2011年12月，加入Arrowhead公司董事会。他在诺华制药公司的干细胞疗法研究的全球总监。2005年至2012年11月，在诺华制药任职之前，他是Bay City Capital LLP公司的投资合伙人。2010年至2012年11月， 他是Poniard制药公司的首席医学官。他现任AmpliPhi Biosciences Corporation APHB.PK 公司和Avita Medical （ASX：AVH and OTCQX：AVMXY）公司的董事。2005年4月至2009年5月，他是VIA制药公司的首席开发官。该公司一家药品研发的上市公司。在那之前，2003年6月至2005年4月，他是 Extropy制药公司的主席兼首席执行官。该公司是一家私营儿科专业制药公司。2002年至2003年，Perry博士担任Baxter 生物科学公司研发部门的全球总监。1997年至2000年，他是SyStemix Inc. 公司和 Genetic Therapy Inc.公司的总裁兼首席执行官。两家公司都是诺华集团的全资子公司。1994年至1997年，他是诺华制药（前身是Sandoz 制药）的法规事务的副总裁。1994年之前，他在辛泰克公司 （Syntex Corporation）、先灵葆雅公司（Schering-Plough Corporation）和BioResearch Laboratories, Inc公司担任过多个管理职务。Perry博士在加拿大安大略省圭而夫大学获得了动物医学博士学位、生物医药理学博士学位、物理学学士学位。他毕业于哈佛商学院国际管理项目系。
- Michael S. Perry is currently a Venture Partner with Bioscience Managers, a global venture capital firm. Dr. Perry was Chief Executive Officer of Avita Medical, Inc., a regenerative medicine company based in Valencia, CA (Nasdaq: RCEL) from 2017 to 2022. From 2014 to 2017, he served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp., the affiliate of Switzerland based Novartis AG, a global pharmaceutical company. Dr. Perry has also served as SVP and Global Head of R&D at Baxter Healthcare, and as President and as CEO of Cell & Gene Therapy at Novartis AG. Earlier in his career he served as VP Regulatory Affairs at Novartis Pharmaceuticals, Sandoz Pharmaceuticals, and Syntex Corporation. He also served as Director of Regulatory Affairs at Schering Plough Corporation. Dr. Perry also served as a Venture Partner with Bay City Capital, LLC for eight years. Dr. Perry has previoly served as a board member for the following companies: Ampliphi Bioscience Corp., Gamida Cell Ltd., Targeted Genetics, Inc., American Xeno, Inc., 7 Hills Pharma, BioTransplant, Inc., ltamar Biomedical Ltd., Systemix, Inc., Genetic Therapy, Inc., Extropy Pharmaceuticals, Inc., and Pharsight Corp. Dr. Perry served as Chair of the Compensation Committee at Ampliphi Bioscience Corp., Genetic Therapy Inc., and at Gamida Cell Ltd. He has also served as a member of the Audit Committee at several biotech companies and as Chairman or member of the Nomination Committee. Dr. Perry additionally served as board Chairman at American Xeno Inc., Extropy Pharmaceuticals Inc., and at 7 Hills Pharma, Inc. Dr. Perry holds an Honors Bachelor of Science in Physics and Engineering and a Ph.D. in Biomedical Pharmacology from the University of Guelph. He also holds a Doctor of Veterinary Medicine & Surgery from the Ontario Veterinary College and is a graduate of the International Advanced Management Program at Harvard Biness School. Dr. Perry currently serves as Adjunct Professor at the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Camp and as Faculty at Hoton Methodist and Chair of the Translational Medicine Advisory Board of the Hoton Methodist Research Institute.
高管简历
中英对照 | 中文 | 英文- Patrick O Brien
Patrick O Brien是总法律顾问，于2014年12月加入本公司。O'Brien先生在医疗保健法律领域开展法律执业超过20年。加入该公司以前，从2012年到2014年，O'Brien先生在Shire任职，他在该公司担任法律部的事业部副总裁。在Shire工作前，他担任国际律师事务所Holland & Knight LLP华盛顿特区办事处的合伙人。O'Brien先生于2010年与人合作创始律所O’Brien Gould PLLC，该公司于2011年与Holland & Knight合并。从2009年至2010年，O'Brien先生是 Burke O'Neil LLC的合伙人。从2001年到2009年，O'Brien先生担任强生公司（Johnson & Johnson）的几个法律职位，包括担任J&J&'s Centocor 奥托生物技术单位的法律部副总裁。在这之前，O'Brien先生担任美国食品药品监督管理局（United States Food & Drug Administration）的监管法律顾问。O'Brien先生在亚利桑那大学（University of Arizona）被授予药学理学学士学位和药学博士学位，之后在伊利诺伊大学（University of Illinois）芝加哥医院（Chicago Hospital）完成临床药学住院医师实习。他还在亚利桑那大学（University of Arizona）被授予法学博士学位。
Patrick O Brien Chief Operating Officer, joined the Company in December 2014, where he has served as Chief Operating Officer since July 2022 and previoly served as General Counsel from 2014 to December 2025. Mr. O'Brien has practiced in the healthcare legal field for over 30 years. Before joining the Company, from 2012 to 2014, Mr. O'Brien was with Shire, a global pharmaceutical company, where he was Group Vice President, Law. Immediately prior to working with Shire, he was a partner with the international law firm of Holland & Knight LLP in its Washington, DC office. In 2010, Mr. O'Brien co founded the law firm O'Brien Gould PLLC which joined Holland & Knight in 2011. From 2009 to 2010, Mr. O'Brien was a partner in Burke O'Neil LLC. From 2001 to 2009, Mr. O'Brien served in several legal roles with Johnson & Johnson, including serving as Vice President of Law for J&J's Centocor Ortho Biotech unit. Mr. O'Brien previoly served as Regulatory Counsel with the United States Food & Drug Administration. Mr. O'Brien was awarded a B.S. in Pharmacy and a Pharm.D. from the University of Arizona before completing a residency in Clinical Pharmacy with the University of Illinois at Chicago Hospital. He was also awarded his J.D. from the University of Arizona.- Patrick O Brien是总法律顾问，于2014年12月加入本公司。O'Brien先生在医疗保健法律领域开展法律执业超过20年。加入该公司以前，从2012年到2014年，O'Brien先生在Shire任职，他在该公司担任法律部的事业部副总裁。在Shire工作前，他担任国际律师事务所Holland & Knight LLP华盛顿特区办事处的合伙人。O'Brien先生于2010年与人合作创始律所O’Brien Gould PLLC，该公司于2011年与Holland & Knight合并。从2009年至2010年，O'Brien先生是 Burke O'Neil LLC的合伙人。从2001年到2009年，O'Brien先生担任强生公司（Johnson & Johnson）的几个法律职位，包括担任J&J&'s Centocor 奥托生物技术单位的法律部副总裁。在这之前，O'Brien先生担任美国食品药品监督管理局（United States Food & Drug Administration）的监管法律顾问。O'Brien先生在亚利桑那大学（University of Arizona）被授予药学理学学士学位和药学博士学位，之后在伊利诺伊大学（University of Illinois）芝加哥医院（Chicago Hospital）完成临床药学住院医师实习。他还在亚利桑那大学（University of Arizona）被授予法学博士学位。
- Patrick O Brien Chief Operating Officer, joined the Company in December 2014, where he has served as Chief Operating Officer since July 2022 and previoly served as General Counsel from 2014 to December 2025. Mr. O'Brien has practiced in the healthcare legal field for over 30 years. Before joining the Company, from 2012 to 2014, Mr. O'Brien was with Shire, a global pharmaceutical company, where he was Group Vice President, Law. Immediately prior to working with Shire, he was a partner with the international law firm of Holland & Knight LLP in its Washington, DC office. In 2010, Mr. O'Brien co founded the law firm O'Brien Gould PLLC which joined Holland & Knight in 2011. From 2009 to 2010, Mr. O'Brien was a partner in Burke O'Neil LLC. From 2001 to 2009, Mr. O'Brien served in several legal roles with Johnson & Johnson, including serving as Vice President of Law for J&J's Centocor Ortho Biotech unit. Mr. O'Brien previoly served as Regulatory Counsel with the United States Food & Drug Administration. Mr. O'Brien was awarded a B.S. in Pharmacy and a Pharm.D. from the University of Arizona before completing a residency in Clinical Pharmacy with the University of Illinois at Chicago Hospital. He was also awarded his J.D. from the University of Arizona.
- James Hamilton
James Hamilton，高级副总裁，发现与转化医学，于2014年加入该公司。他负责目标发现以及非临床和早期临床开发。此前，Hamilton博士曾担任临床开发Vice President，负责临床策略、临床试验设计和执行，包括所有箭头项目的早期转化和中期开发。他在多个疾病领域经验丰富，包括病毒学、肝脏学、心血管疾病、罕见病和肿瘤学。Hamilton博士领导ARO-HBV（现为JNJ-3989）的临床开发，该公司已获得Janssen Pharmaceuticals的许可。与此同时，Hamilton博士曾担任公司开发主管，并领导Novartis&8217；RNAi Assets的Arrowhead&8217；s许可交易，以及ARO-LPA（现为AMG890）向Amgen的许可以及ARO-AAT与武田的合作伙伴关系。Hamilton博士在箭头公司（Arrowhead）开始任职，担任医疗总监和企业发展主管。他持有俄亥俄州立大学（the Ohio State University）的医学博士和工商管理硕士学位。他是一名有执照的医生，并完成了急诊医学的董事会认证的住院医师培训。
James Hamilton Chief Medical Officer and Head of R&D, joined the Company in 2014, where he has served as Chief Medical Officer since February 2025. He previoly served as Chief of Discovery & Translational Medicine, and was responsible for target discovery as ll as non clinical and early clinical development. Prior to that, Dr. Hamilton served as Vice President, Clinical Development, and was responsible for clinical strategy, clinical trial design and execution including early translational and mid stage development of all Arrowhead programs. He is experienced in multiple disease areas including virology, hepatology, cardiovascular disease, rare disease and oncology. Dr. Hamilton led the clinical development of ARO HBV (now JNJ 3989), which was licensed to Janssen Pharmaceuticals. In parallel, Dr. Hamilton served as Head of Corporate Development and led Arrowhead's in licensing transaction of Novartis's RNAi assets, as ll as the out licensing of ARO LPA (now AMG890) to Amgen and the ARO AAT partnership with Takeda. Dr. Hamilton started his employment at Arrowhead as Medical Director and Head of Corporate development. He holds both M.D. and M.B.A. degrees from The Ohio State University. He is a licensed physician and completed residency training with board certification in emergency medicine.- James Hamilton，高级副总裁，发现与转化医学，于2014年加入该公司。他负责目标发现以及非临床和早期临床开发。此前，Hamilton博士曾担任临床开发Vice President，负责临床策略、临床试验设计和执行，包括所有箭头项目的早期转化和中期开发。他在多个疾病领域经验丰富，包括病毒学、肝脏学、心血管疾病、罕见病和肿瘤学。Hamilton博士领导ARO-HBV（现为JNJ-3989）的临床开发，该公司已获得Janssen Pharmaceuticals的许可。与此同时，Hamilton博士曾担任公司开发主管，并领导Novartis&8217；RNAi Assets的Arrowhead&8217；s许可交易，以及ARO-LPA（现为AMG890）向Amgen的许可以及ARO-AAT与武田的合作伙伴关系。Hamilton博士在箭头公司（Arrowhead）开始任职，担任医疗总监和企业发展主管。他持有俄亥俄州立大学（the Ohio State University）的医学博士和工商管理硕士学位。他是一名有执照的医生，并完成了急诊医学的董事会认证的住院医师培训。
- James Hamilton Chief Medical Officer and Head of R&D, joined the Company in 2014, where he has served as Chief Medical Officer since February 2025. He previoly served as Chief of Discovery & Translational Medicine, and was responsible for target discovery as ll as non clinical and early clinical development. Prior to that, Dr. Hamilton served as Vice President, Clinical Development, and was responsible for clinical strategy, clinical trial design and execution including early translational and mid stage development of all Arrowhead programs. He is experienced in multiple disease areas including virology, hepatology, cardiovascular disease, rare disease and oncology. Dr. Hamilton led the clinical development of ARO HBV (now JNJ 3989), which was licensed to Janssen Pharmaceuticals. In parallel, Dr. Hamilton served as Head of Corporate Development and led Arrowhead's in licensing transaction of Novartis's RNAi assets, as ll as the out licensing of ARO LPA (now AMG890) to Amgen and the ARO AAT partnership with Takeda. Dr. Hamilton started his employment at Arrowhead as Medical Director and Head of Corporate development. He holds both M.D. and M.B.A. degrees from The Ohio State University. He is a licensed physician and completed residency training with board certification in emergency medicine.
- Daniel Apel
Daniel Apel 首席财务官,2025年4月加入Arrowhead担任首席财务官。Apel先生为Arrowhead带来了超过25年的全球金融经验。在加入Arrowhead之前，他于2019年6月至2024年6月在沃尔格林联合博姿WBA（一家医疗保健、药房和零售公司）担任财务规划和分析全球主管，负责全球财务规划和分析。Apel先生在拜耳近20年的职业生涯中还担任过多种职务，包括2016年至2019年担任拜耳美国公司的首席财务官、拜耳加拿大公司的首席财务官以及拜耳医疗保健部门的全球会计主管，总部设在德国。他曾在生物技术创新组织（BIO）和国际投资组织的董事会任职，并担任新泽西州卫生研究所的首席财务官。Apel先生在加州大学伯克利分校获得BINCE Administration硕士学位，在宾夕法尼亚大学获得文学学士学位，并且是一名持牌注册会计师。
Daniel Apel Chief Financial Officer, joined Arrowhead as Chief Financial Officer in April 2025. Mr. Apel has over 25 years of and global financial experience to Arrowhead. Prior to joining Arrowhead he served as Global Head of Financial Planning and Analysis from June 2019 through June 2024 at Walgreens Boots Alliance WBA, a healthcare, pharmacy and retail company, where he was responsible for global financial planning and analysis. Mr. Apel also served in vario capacities in his nearly 20 year career at Bayer, including as Chief Financial Officer for Bayer U.S. from 2016 through 2019, as Chief Financial Officer for Bayer Canada and as global Head of Accounting for the Bayer Healthcare Segment, based in Germany. He served on the boards of the Biotechnology Innovation Organization (BIO) and the Organization for International Investment, as ll as a Trtee for the Health Institute of New Jersey. Mr. Apel earned his Master's degree in Biness Administration from the University of California, Berkeley, a Bachelor's of Arts Degree from the University of Pennsylvania, and is a licensed Certified Public Accountant.- Daniel Apel 首席财务官,2025年4月加入Arrowhead担任首席财务官。Apel先生为Arrowhead带来了超过25年的全球金融经验。在加入Arrowhead之前，他于2019年6月至2024年6月在沃尔格林联合博姿WBA（一家医疗保健、药房和零售公司）担任财务规划和分析全球主管，负责全球财务规划和分析。Apel先生在拜耳近20年的职业生涯中还担任过多种职务，包括2016年至2019年担任拜耳美国公司的首席财务官、拜耳加拿大公司的首席财务官以及拜耳医疗保健部门的全球会计主管，总部设在德国。他曾在生物技术创新组织（BIO）和国际投资组织的董事会任职，并担任新泽西州卫生研究所的首席财务官。Apel先生在加州大学伯克利分校获得BINCE Administration硕士学位，在宾夕法尼亚大学获得文学学士学位，并且是一名持牌注册会计师。
- Daniel Apel Chief Financial Officer, joined Arrowhead as Chief Financial Officer in April 2025. Mr. Apel has over 25 years of and global financial experience to Arrowhead. Prior to joining Arrowhead he served as Global Head of Financial Planning and Analysis from June 2019 through June 2024 at Walgreens Boots Alliance WBA, a healthcare, pharmacy and retail company, where he was responsible for global financial planning and analysis. Mr. Apel also served in vario capacities in his nearly 20 year career at Bayer, including as Chief Financial Officer for Bayer U.S. from 2016 through 2019, as Chief Financial Officer for Bayer Canada and as global Head of Accounting for the Bayer Healthcare Segment, based in Germany. He served on the boards of the Biotechnology Innovation Organization (BIO) and the Organization for International Investment, as ll as a Trtee for the Health Institute of New Jersey. Mr. Apel earned his Master's degree in Biness Administration from the University of California, Berkeley, a Bachelor's of Arts Degree from the University of Pennsylvania, and is a licensed Certified Public Accountant.
- Christopher Anzalone
Christopher Anzalone， 2007年12月1日，他成为公司的总裁、首席执行官及董事。2005年，Anzalone博士在Benet Group LLC公司担任首席执行官。Benet Group LLC是一家创建纳米生物科技公司的私募股权公司。在Benet集团工作期间，他是两家投资组合公司Nanotope公司（一家研究组织再生的公司）和Leonardo Biosystems公司（一家癌症药物递送公司）的创业总裁。他是Arrowhead公司全资控股子公司Arrowhead Madison 公司和多数控股子公司Calando 制药、Ablaris Therapeutics公司、Tego Biosciences公司，以及少数投资公司Leonardo Biosystems的董事。1999年至2003年，他是华盛顿特区私人股本公司Galway Partners, LLC的合伙人。他在该公司负责采购、组织和建立新企业。他是NanoInk公司（一家领先的纳米公司）的创业总裁。他在加州大学洛杉矶分校获得生物学博士学位；在劳伦斯大学获得管理学学士学位。
Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007 and has led the Company's biness and technical development since then. Prior to joining Arrowhead, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm foced on creating and building new nano biotechnology companies from university generated science. Before his tenure at the Benet Group, from 1999 to 2003, he was a partner at the Washington, DC based private equity firm Galway Partners, LLC, where he was responsible for scing, structuring and building new biness ventures. Dr. Anzalone holds a Ph.D in Biology from UCLA and a B.A. in Government from Lawrence University.- Christopher Anzalone， 2007年12月1日，他成为公司的总裁、首席执行官及董事。2005年，Anzalone博士在Benet Group LLC公司担任首席执行官。Benet Group LLC是一家创建纳米生物科技公司的私募股权公司。在Benet集团工作期间，他是两家投资组合公司Nanotope公司（一家研究组织再生的公司）和Leonardo Biosystems公司（一家癌症药物递送公司）的创业总裁。他是Arrowhead公司全资控股子公司Arrowhead Madison 公司和多数控股子公司Calando 制药、Ablaris Therapeutics公司、Tego Biosciences公司，以及少数投资公司Leonardo Biosystems的董事。1999年至2003年，他是华盛顿特区私人股本公司Galway Partners, LLC的合伙人。他在该公司负责采购、组织和建立新企业。他是NanoInk公司（一家领先的纳米公司）的创业总裁。他在加州大学洛杉矶分校获得生物学博士学位；在劳伦斯大学获得管理学学士学位。
- Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007 and has led the Company's biness and technical development since then. Prior to joining Arrowhead, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm foced on creating and building new nano biotechnology companies from university generated science. Before his tenure at the Benet Group, from 1999 to 2003, he was a partner at the Washington, DC based private equity firm Galway Partners, LLC, where he was responsible for scing, structuring and building new biness ventures. Dr. Anzalone holds a Ph.D in Biology from UCLA and a B.A. in Government from Lawrence University.